A phase II, double-blind, placebo-controlled clinical trial to assess celecoxib as a chemopreventive agent inhibiting UV-induced erythema and cutaneous carcinogenesis as assessed through surrogate biological markers in biopsied skin after exposure of skin in normal volunteers ages 20-60 years old with Fitzpatrick type I, II, III and IV skin to UV-radiation from artificial light sources

Trial Profile

A phase II, double-blind, placebo-controlled clinical trial to assess celecoxib as a chemopreventive agent inhibiting UV-induced erythema and cutaneous carcinogenesis as assessed through surrogate biological markers in biopsied skin after exposure of skin in normal volunteers ages 20-60 years old with Fitzpatrick type I, II, III and IV skin to UV-radiation from artificial light sources

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2006 Status change
    • 26 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top